Summary
QTS Chart
IQVIA: Increasingly Indispensable In Drug Development
IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record $32.4B backlog, technology-driven margin expansion, and robust buyback-enhanced EPS growth. IQV's unique, comprehensive data assets and AI-enabled services create a defensible moat, insulating it from both Big Tech and CRO competition.
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is IQVIA (IQV) Up 6.4% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
IQVIA Holdings Inc. (QTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has IQVIA Holdings Inc. ever had a stock split?
IQVIA Holdings Inc. Profile
| Professional Services Industry | Industrials Sector | Ari Bousbib CEO | XSTU Exchange | US46266C1053 ISIN |
| US Country | 89,000 Employees | - Last Dividend | - Last Split | 9 May 2013 IPO Date |
Overview
IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.
Products and Services
- Technology & Analytics Solutions
- Research & Development Solutions
- Contract Sales & Medical Solutions
This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.
This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.
Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.
Contact Information
